| 周娟 王泳晓 何志群 何丽亚 陈广峰 黄德秋.导流杂交HPV-DNA分型检测联合宫颈液基细胞学对宫颈癌前病变筛查的临床应用研究[J].实用中西医结合临床,2014,14(7):58-60 |
| 导流杂交HPV-DNA分型检测联合宫颈液基细胞学对宫颈癌前病变筛查的临床应用研究 |
| Clinical Application of HibriMax HPV-DNA Genotyping Combined with Liquid-based Cytology for Screening Precancerous Lesions of Uterine Cervix |
| |
| DOI： |
| 中文关键词: 导流交杂HPV-DNA分型检测 宫颈液基细胞学 宫颈癌前病变 筛查效果 |
| 英文关键词: HibriMax HPV-DNA genotyping Liquid-based cytology Precancerous lesions of uterine cervix Screening accuracy |
| 基金项目: |
|
| 摘要点击次数: 654 |
| 全文下载次数: 404 |
| 中文摘要: |
| 目的：探讨导流杂交HPV-DNA分型检测联合宫颈液基细胞学对宫颈癌前病变筛查效果。方法：本研究将自愿接受宫颈癌前病变筛查的妇女265例行导流杂交HPV-DNA分型检测联合宫颈液基细胞学检测，对导流杂交HPV-DNA高危型检测阳性和/或宫颈液基细胞学检测阳性者，再行阴道镜检查，对阴道镜下发现可疑病灶者行宫颈组织病理学检查，以宫颈组织病理学诊断为最后确诊标准。结果：（1）265例患者经宫颈液基细胞学检查阳性者19例；经导流杂交HPV-DNA分型检测检出高危型阳性者共75例；最后经阴道镜下宫颈组织病理学诊断为宫颈癌前病变及宫颈癌者25例。（2）宫颈液基细胞学检查阳性的19例患者中，经病理检查确诊为宫颈癌前病变及宫颈癌的17例，与两者联合筛查最后病理确诊宫颈癌前病变及宫颈癌者（即阳性者）25例，检出阳性符合率68.00%。导流杂交HPV-DNA分型检测检出高危型检测阳性者75例中，最后经病理检查确诊为宫颈癌前病变及宫颈癌的23例，与两者联合筛查最后病理确诊宫颈癌前病变及宫颈癌者（即阳性者）25例，检出阳性符合率92.00%。两者有统计学意义（P<0.05）。结论：导流杂交HPV-DNA分型检测联合宫颈液基细胞学是目前最合理的宫颈癌前病变筛查方案，可以最大程度降低漏诊率，且与病理学诊断符合率极高。 |
| 英文摘要: |
| Objective: To study clinical effect of HibriMax HPV-DNA genotyping combined with liquid-based cytology for screening precancerous lesions of uterine cervix. Methods: 265 subjects taking screening of precancerous lesions of uterine cervix voluntarily were applied to HibriMax HPV-DNA genotyping combined with liquid-based cytology. Subjects proved to be positive high risk type by HibriMax HPV-DNA genotyping and (or) liquid-based cytology were given a colposcopy exam and subjects detected with suspected nidus were given a histopathological exam, the results of which were taken as final diagnosises. Results: (1) of all 256 subjects, 19 were found positive using liquid based cytology, 75 were detected as positive high-risk type by HibriMax HPV-DNA genotyping, 25 were confirmed of precancerous lesions of cervical cancer by histopathological exam. (2) of the 19 subjects found positive using liquid based cytology, 17 were confirmed of precancerous lesions of cervical cancer by histopathological exam. Applying HibriMax HPV-DNA genotyping combined with liquid-based cytology, totally 25 were detected positive and confirmed of precancerous lesions of cervical cancer by histopathological exam, the matching rate being 68.00%. Of the 75 subjects detected positive high risk type by HibriMax HPV-DNA genotyping, 23 were confirmed of precancerous lesions of cervical cancer by histopathological exam. Applying HibriMax HPV-DNA genotyping combined with liquid-based cytology, totally 25 were detected positive and later confirmed of precancerous lesions of cervical cancer by histopathological exam, the matching rate being 92.00%. Both proved statistical significance (P<0.05). Conclusion: HibriMax HPV-DNA genotyping combined with liquid-based cytology is the most advanced screening method for precancerous lesions of cervical cancer, and it proves maximum accuracy and promises highest matching rates with pathological diagnosises. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
